Iambic Therapeutics

Iambic Therapeutics is a clinical-stage biopharmaceutical company in San Diego that pairs AI-driven molecular design with automated chemical synthesis and high-throughput experimentation. Its platform combines physics-informed machine learning models with laboratory execution to complete drug design-make-test cycles on a weekly cadence. Iambic advances its own oncology pipeline of brain-penetrant small-molecule inhibitors and also licenses the platform to pharmaceutical partners including Bayer and Revolution Medicines. Its lead candidate moved from program initiation into human trials in roughly two years.

Physics-informed AI architectures (NeuralPLexer for protein-ligand co-folding, Enchant for multimodal property prediction) tightly coupled to automated synthesis, allowing weekly design-make-test cycles and dramatically compressed timelines from program start to clinical trials.